Rain Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Rain Therapeutics Inc. (NasdaqGS: RAIN) announced that CEO Avanish Vellanki will present at two upcoming virtual conferences: the JP Morgan Chase 40th Annual Healthcare Conference on January 13, 2022, and the H.C. Wainwright Bioconnect Conference starting January 10, 2022. The JP Morgan presentation will be live at 11:15 a.m. ET, while H.C. Wainwright will feature a prerecorded session available from 7:00 a.m. ET. Both events highlight Rain's focus on precision oncology, targeting therapies for genetically selected patients.

NEWARK, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will provide a corporate overview at the JP Morgan Chase 40^th Annual Healthcare Conference and at the H.C. Wainwright Bioconnect Conference, both conferences being held virtually January 10-13, 2022.

Additional details can be found below:

Conference: JP Morgan Chase 40^th Annual Healthcare Conference
Date and Time: Thursday, January 13, 2022 at 11:15 a.m. ET
Location: Webcast Link - or at the company’s website (click here)

Conference: H.C. Wainwright Bioconnect Conference
Date and Time: Prerecorded presentation will be available beginning Monday, January 10, 2022 at 7:00 a.m. ET
Location: Webcast Link - or at the company’s website (click here)

Replay of the corporate overview presentation will be available by visiting the "Events & Presentations" section of the Rain website after the conclusion of the presentation and will be archived on the Rain website for 30 days.

About Rain Therapeutics Inc.
Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Media Contact
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com

Investor Contact
Bob Yedid
LifeSci Advisors
+1.646.597.6989
bob@lifesciadvisors.com

FAQ

When is Rain Therapeutics presenting at the JP Morgan Chase 40th Annual Healthcare Conference?

Rain Therapeutics will present at the JP Morgan Chase 40th Annual Healthcare Conference on January 13, 2022, at 11:15 a.m. ET.

What is the date and time for the H.C. Wainwright Bioconnect Conference presentation by Rain Therapeutics?

The H.C. Wainwright Bioconnect Conference presentation will be available starting January 10, 2022, at 7:00 a.m. ET.

How can I access Rain Therapeutics' conference webcasts?

Webcasts for the conferences can be accessed through the provided links on Rain Therapeutics' official website.

What is Rain Therapeutics' focus in precision oncology?

Rain Therapeutics focuses on developing therapies that target oncogenic drivers and genetically select patients for their treatments.

What is the lead product candidate of Rain Therapeutics?

The lead product candidate of Rain Therapeutics is milademetan, an oral inhibitor of MDM2 targeted at various cancers.